Reimbursed Care Access in Djibouti

Currently classified as a strictly controlled psychotropic substance under Djibouti’s national drug-control legislation (Loi No. 171/AN/81), with no authorized medical framework, reimbursement, or licensed therapeutic programs for psilocybin outside of approved clinical research. Access for non-research medical use is not established; possession, distribution, or trafficking are criminal offences under the national law. #

Currently classified as a strictly controlled substance under Djibouti’s national drug-scheduling regime, with no authorized medical MDMA therapy programs, reimbursement, or regulatory approval for therapeutic MDMA-assisted treatment outside approved clinical research. Standard criminal sanctions apply for possession, trafficking, or distribution. #

Esketamine (intranasal esketamine products used in some countries for treatment-resistant depression) is not known to have an approved marketing, reimbursement, or established regulatory pathway in Djibouti. There is no public record of national approval, public reimbursement, or routine clinical availability; if any access exists it would be limited to tightly controlled importation for authorised clinical trials or special permission by health authorities. The general national drug-control law governs psychotropic and narcotic imports and use. #

Ketamine is widely recognised on the WHO Model List of Essential Medicines as an injectable anaesthetic, indicating its importance in medical care globally; however, in Djibouti all narcotic/psychotropic importation, possession and distribution are governed by strict national controls (Loi No. 171/AN/81). This means any legitimate medical use of ketamine in Djibouti would be subject to licensing, importation controls and oversight by health authorities; there is no publicly available evidence of a formal national reimbursement program for ketamine for psychiatric indications (e.g., for depression). Routine hospital use of ketamine as an anaesthetic is consistent with global practice where ketamine is included on essential medicines lists, but local prescribing, procurement and any insurance coverage would follow Djiboutian Ministry of Health procedures and narcotics regulation. Sources: WHO listing of ketamine on the Model List of Essential Medicines; Djibouti national psychotropic substances law. #; #

Currently classified as a strictly controlled psychotropic substance under Djibouti’s national drug laws, with no authorized medical or reimbursed access for DMT outside of approved research contexts. There is no public regulatory framework for therapeutic DMT or insurance reimbursement in Djibouti. #

Currently classified as a strictly controlled psychotropic substance under Djibouti’s national drug-scheduling law, with no authorised medical use or reimbursement pathway; access is limited to approved clinical research only if permitted by national authorities. #

Currently classified as a strictly controlled substance under national drug-control statutes in Djibouti, with no recognized medical/therapeutic licensing or reimbursement for ibogaine; access only possible through authorised clinical research (if approved) and otherwise is criminalised. #

Currently classified under Djibouti’s psychotropic/narcotics legal framework with no authorised therapeutic program or reimbursement; traditional or ritual use involving DMT-containing brews would be treated under the same national controls unless a formal, authorised research exemption exists. Access outside research is criminalised. #

Currently classified as a strictly controlled substance under Djibouti’s national drug laws, with no established medical approval or reimbursement for mescaline-containing cacti or purified mescaline outside of approved clinical research. Possession, trafficking, or non-authorised distribution are criminal offences. #

Currently classified as a strictly controlled synthetic psychotropic category under Djibouti’s drug-control legislation, with no authorised medical use or reimbursement; access is restricted to authorised scientific/clinical research if permitted by national authorities. Criminal penalties apply for unauthorised possession, manufacture or distribution. #